A Phase 3 interventional study of Orforglipron and Placebo in Obesity, sponsored by Eli Lilly and Company. Completed at 16 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing orforglipron in Obesity — 4 open to participants now, 10 under way, 9 of them phase 3. orforglipron · Obesity.
Among the 22 studies testing orforglipron in Obesity, this one is the 13th largest by enrollment, is one of 6 that started in 2023, is one of 14 in phase 3, and was the 7th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →4 of the 22 studies testing orforglipron in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Belgium, Brazil and 10 more countries
Ages 6–17
Eli Lilly and Company · Sites in United States, Israel, Italy and 3 more countries
Ages 12–17
Eli Lilly and Company · Sites in China
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18–80
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, orforglipron is the treatment under test here. Read study by study →
22 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 238 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 324 across the 22 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 22 have an industry lead sponsor. The 2 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 63rd largest by enrollment of the 117 interventional ones that give a count, is one of 21 that started in 2023, is one of 51 in phase 3, and was the 34th registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
5 of the studies testing orforglipron in Obesity that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
| NCT06972459Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | 2027-08 |
| NCT06972472Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | 2027-08 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 22 studies testing orforglipron in Obesity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For participants with Type 2 Diabetes (T2D):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received matching placebo capsule orally once daily (QD). Treatment was initiated with placebo corresponding to 1 mg equivalent to Orforglipron, with dose escalation every 4 weeks to maintain blinding, and was continued through Week 72, unless dose interruption or modification was required. Treatment was administered as an adjunct to a reduced-calorie diet and increased physical activity.
Drug: Placebo
Participants received oral orforglipron capsule once daily. Treatment was initiated at 1 mg once daily, with dose escalation every 4 weeks to a target dose of 6 mg, which was maintained through Week 72, unless dose interruption or modification was required. Treatment was administered as an adjunct to a reduced-calorie diet and increased physical activity.
Drug: Orforglipron
Participants received oral orforglipron capsule once daily. Treatment was initiated at 1 mg once daily, with dose escalation every 4 weeks to a target dose of 12 mg, which was maintained through Week 72, unless dose interruption or modification was required. Treatment was administered as an adjunct to a reduced-calorie diet and increased physical activity.
Drug: Orforglipron
Participants received oral orforglipron capsule once daily. Treatment was initiated at 1 mg once daily, with dose escalation every 4 weeks to a target dose of 36 mg, which was maintained through Week 72, unless dose interruption or modification was required. Treatment was administered as an adjunct to a reduced-calorie diet and increased physical activity.
Drug: Orforglipron
Administered orally
Administered orally
Percent Change From Baseline in Body Weight at Week 72
Values reported as "LS Mean" are model-based estimates (MBE) of the adjusted (unconditional) treatment effect. MBEs was calculated using an analysis of covariance (ANCOVA) model with the following variables: treatment group, baseline value, baseline Body Mass Index (BMI) category (\<35 kilogram per meter square \[kg/m²\] or ≥35 kg/m²), and stratification factors (sex and baseline type 2 diabetes status). Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).
Time frame: Baseline, Week 72
Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline
Percentage of participants with ≥5% body weight reduction was analysed by Logistic regression with the following variables: treatment group, baseline value, baseline BMI category (\<35 kg/m² or ≥35 kg/m²), and stratification factors (sex and baseline type 2 diabetes status). Stratification factors were defined by the combination of sex (female, male) and baseline type 2 diabetes status (yes, no). The model also allowed the treatment effect to vary across baseline values and stratification factors.
Time frame: Baseline to Week 72
Percentage of Participants Who Achieved ≥10% Body Weight Reduction From Baseline
Percentage of participants with ≥10% body weight reduction was analysed by Logistic regression with the following variables: treatment group, baseline value, baseline BMI category (\<35 kg/m² or ≥35 kg/m²), and stratification factors (sex and baseline type 2 diabetes status). Stratification factors were defined by the combination of sex (female, male) and baseline type 2 diabetes status (yes, no). The model also allowed the treatment effect to vary across baseline values and stratification factors.
Time frame: Baseline to Week 72
Percentage of Participants Who Achieved ≥15% Body Weight Reduction From Baseline
Percentage of participants with ≥15% body weight reduction was analysed by Logistic regression with the following variables: treatment group, baseline value, baseline BMI category (\<35 kg/m² or ≥35 kg/m²), and stratification factors (sex and baseline type 2 diabetes status). Stratification factors were defined by the combination of sex (female, male) and baseline type 2 diabetes status (yes, no). The model also allowed the treatment effect to vary across baseline values and stratification factors.
Time frame: Baseline to Week 72
Percentage of Participants Who Achieved ≥20% Body Weight Reduction From Baseline
Percentage of participants with ≥20% body weight reduction was analysed by Logistic regression with the following variables: treatment group, baseline value, baseline BMI category (\<35 kg/m² or ≥35 kg/m²), and stratification factors (sex and baseline type 2 diabetes status). Stratification factors were defined by the combination of sex (female, male) and baseline type 2 diabetes status (yes, no). The model also allowed the treatment effect to vary across baseline values and stratification factors.
Time frame: Baseline to Week 72
Change From Baseline in Body Mass Index (BMI) at Week 72
Values reported as "LS Mean" are model-based estimates (MBE) of the adjusted (unconditional) treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no). The model also allowed the treatment effect to vary across baseline values and stratification factors.
Time frame: Baseline, Week 72
Percentage of Participants Who Had Improvements in Hypertension
Percentage of participants achieving hypertension improvement ((Systolic blood pressure \<130 mmHg and diastolic blood pressure \<80 mmHg) was analysed using logistic regression with the following variables: treatment, baseline BMI group, and strata in the model. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no). The estimates (odds ratio and corresponding confidence intervals) were derived using observed data.
Time frame: Baseline to Week 72
Percentage of Participants Who Had Improvements in Dyslipidemia
Percentage of participants achieving dyslipidemia improvement (Low-density lipoprotein cholesterol \<140 milligrams per deciliter (mg/dL), triglycerides \<150 mg/dL, and high-density lipoprotein cholesterol ≥40 mg/dL) was analysed using logistic regression with the following variables: treatment, baseline BMI group, and strata in the model. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no). The estimates (odds ratio and corresponding confidence intervals) were derived using observed data.
Time frame: Baseline to Week 72
Percentage of Participants Who Achieve Hemoglobin A1c (HbA1c) Target Value (<6.5% [48 mmol/Mol])
Percentage of participants achieving HbA1c \<6.5% was analysed using logistic regression with the following variables: baseline, treatment, baseline BMI group, and sex in the model, including treatment-by-baseline and treatment-by-sex interaction terms.
Time frame: Baseline to Week 72
Mean Change From Baseline in Visceral Adipose Tissue (VAT) at Week 72
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).
Time frame: Baseline, Week 72
Mean Change From Baseline in Waist Circumference at Umbilical Level at Week 72
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).
Time frame: Baseline, Week 72
Mean Change From Baseline in Systolic Blood Pressure (SBP) at Week 72
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).
Time frame: Baseline, Week 72
Percent Change From Baseline in Non-High Density Lipoprotein (Non-HDL) at Week 72
Values represented as LS means are model-based estimates (MBE) of the unconditional average treatment effect on the log-transformed scale. MBE was calculated using an ANCOVA model for log(Actual Value/Baseline), including log-transformed baseline, treatment, baseline BMI group, and strata (defined by joint levels of sex \[female, male\] and baseline type 2 diabetes status \[yes, no\]) as covariates, with treatment-by-log(baseline) and treatment-by-strata interaction terms included in the model.
Time frame: Baseline, Week 72
Percent Change From Baseline in High Density Lipoprotein (HDL) at Week 72
Values represented as LS means are model-based estimates (MBE) of the unconditional average treatment effect on the log-transformed scale. MBE was calculated using an ANCOVA model for log(Actual Value/Baseline), including log-transformed baseline, treatment, baseline BMI group, and strata (defined by joint levels of sex \[female, male\] and baseline type 2 diabetes status \[yes, no\]) as covariates, with treatment-by-log(baseline) and treatment-by-strata interaction terms included in the model.
Time frame: Baseline, Week 72
Percent Change From Baseline in Triglycerides at Week 72
Values represented as LS means are model-based estimates (MBE) of the unconditional average treatment effect on the log-transformed scale. MBE was calculated using an ANCOVA model for log(Actual Value/Baseline), including log-transformed baseline, treatment, baseline BMI group, and strata (defined by joint levels of sex \[female, male\] and baseline type 2 diabetes status \[yes, no\]) as covariates, with treatment-by-log(baseline) and treatment-by-strata interaction terms included in the model.
Time frame: Baseline, Week 72
Mean Change From Baseline in Fasting Glucose at Week 72
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).
Time frame: Baseline, Week 72
Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 72
* Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over prolonged periods of time. * Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).
Time frame: Baseline, Week 72
Mean Change From Baseline in High-sensitivity C-reactive Protein at Week 72
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed model for repeated measures (MMRM) with the following variables: baseline BMI group, baseline-by-time-by-treatment, and strata-by-time-by-treatment interaction terms in the model. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no). An unstructured variance-covariance matrix was used.
Time frame: Baseline, Week 72
Time to Onset of Type 2 Diabetes (T2D)
Time to event was defined as the duration from randomization to adjudication committee-confirmed diagnosis of type 2 diabetes mellitus (T2D). Descriptive statistics are presented as Kaplan-Meier estimates of time to onset of T2D (in weeks). Time to onset of T2D was also analyzed using a Cox proportional hazards model, with treatment (pooled orforglipron dose groups) and sex as factors and baseline fasting serum glucose as a covariate. Hazard ratios with corresponding confidence intervals were estimated and reported in statistical analysis. Statistical significance between treatment groups was assessed using a two-sided log-rank test.
Time frame: Up to Week 72
Mean Change From Baseline in Short Form 36 Version 2 (SF-36v2) Acute Form For Domain and Component Scores at Week 72
The SF-36v2 acute form, 1-week recall assesses participants' health-related quality of life on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. Each domain is scored individually and information from these 8 domains is further aggregated into 2 health component summary scores, a Physical Component Summary, and a Mental Component Summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T scores, with mean of 50 and standard deviation of 10; higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.
Time frame: Baseline, Week 72
Mean Change From Baseline in Impact of Weight on Quality-of-Life Lite Clinical Trials Version (IWQOL-Lite-CT) of Physical Function, Physical, and Psychosocial Composite Score at Week 72
The IWQOL-Lite-CT is a 20-item, obesity-specific patient reported outcome instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life: physical (7 items), and psychosocial (13 items). A 5-item subset of the physical domain, the physical-function composite is also supported. Items in the physical-function composite describe physical impacts related to general and specific physical activities. All items are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. The two domain scores (Physical and Psychosocial) and composite score (Physical function) range from 0 to 100 with higher scores indicating greater functioning. Raw scores are then linearly transformed to a 0 (worst) -100 (best) scale using: 100×(average item score-1)/4. Higher scores indicate better quality of life/function; lower scores indicate greater impairment.
Time frame: Baseline, Week 72
Pharmacokinetics (PK): Mean Plasma Concentration of Orforglipron
Plasma concentrations of orforglipron were measured at predefined pre-dose and post-dose sampling time points.
Time frame: Pre-dose at Weeks 8, 24, and 48; post-dose at Week 16 (4 to 12 hours) and Week 36 (1 to 4 hours)
| Milestone | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Started | 60 | 61 | 57 | 60 |
| Received at least one dose of study drug | 60 | 61 | 57 | 60 |
| Completed | 54 | 54 | 52 | 54 |
| Not completed | 6 | 7 | 5 | 6 |
| Withdrew: Adverse event | 0 | 1 | 2 | 2 |
| Withdrew: Death | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 1 | 1 | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 5 | 1 | 2 |
Values reported as "LS Mean" are model-based estimates (MBE) of the adjusted (unconditional) treatment effect. MBEs was calculated using an analysis of covariance (ANCOVA) model with the following variables: treatment group, baseline value, baseline Body Mass Index (BMI) category (\<35 kilogram per meter square \[kg/m²\] or ≥35 kg/m²), and stratification factors (sex and baseline type 2 diabetes status). Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).
| percent change | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percent Change From Baseline in Body Weight at Week 72 | -0.63 ± 0.732 | -5.90 ± 0.866 | -8.69 ± 1.136 | -7.93 ± 1.063 |
Percentage of participants with ≥5% body weight reduction was analysed by Logistic regression with the following variables: treatment group, baseline value, baseline BMI category (\<35 kg/m² or ≥35 kg/m²), and stratification factors (sex and baseline type 2 diabetes status). Stratification factors were defined by the combination of sex (female, male) and baseline type 2 diabetes status (yes, no). The model also allowed the treatment effect to vary across baseline values and stratification factors.
| Percentage of Participants | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline | 15.00 | 45.90 | 61.40 | 58.33 |
Percentage of participants with ≥10% body weight reduction was analysed by Logistic regression with the following variables: treatment group, baseline value, baseline BMI category (\<35 kg/m² or ≥35 kg/m²), and stratification factors (sex and baseline type 2 diabetes status). Stratification factors were defined by the combination of sex (female, male) and baseline type 2 diabetes status (yes, no). The model also allowed the treatment effect to vary across baseline values and stratification factors.
| Percentage of Participants | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percentage of Participants Who Achieved ≥10% Body Weight Reduction From Baseline | 3.33 | 18.03 | 35.09 | 38.33 |
Percentage of participants with ≥15% body weight reduction was analysed by Logistic regression with the following variables: treatment group, baseline value, baseline BMI category (\<35 kg/m² or ≥35 kg/m²), and stratification factors (sex and baseline type 2 diabetes status). Stratification factors were defined by the combination of sex (female, male) and baseline type 2 diabetes status (yes, no). The model also allowed the treatment effect to vary across baseline values and stratification factors.
| Percentage of Participants | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percentage of Participants Who Achieved ≥15% Body Weight Reduction From Baseline | 0 | 9.84 | 22.81 | 18.33 |
Percentage of participants with ≥20% body weight reduction was analysed by Logistic regression with the following variables: treatment group, baseline value, baseline BMI category (\<35 kg/m² or ≥35 kg/m²), and stratification factors (sex and baseline type 2 diabetes status). Stratification factors were defined by the combination of sex (female, male) and baseline type 2 diabetes status (yes, no). The model also allowed the treatment effect to vary across baseline values and stratification factors.
| Percentage of Participants | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percentage of Participants Who Achieved ≥20% Body Weight Reduction From Baseline | 0 | 3.28 | 12.28 | 8.33 |
Values reported as "LS Mean" are model-based estimates (MBE) of the adjusted (unconditional) treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no). The model also allowed the treatment effect to vary across baseline values and stratification factors.
| kilograms per meter square (kg/m^2) | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Change From Baseline in Body Mass Index (BMI) at Week 72 | -0.21 ± 0.230 | -1.94 ± 0.271 | -2.83 ± 0.354 | -2.63 ± 0.355 |
Percentage of participants achieving hypertension improvement ((Systolic blood pressure \<130 mmHg and diastolic blood pressure \<80 mmHg) was analysed using logistic regression with the following variables: treatment, baseline BMI group, and strata in the model. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no). The estimates (odds ratio and corresponding confidence intervals) were derived using observed data.
| Percentage of Participants | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percentage of Participants Who Had Improvements in Hypertension | 14.9 | 34.7 | 30.0 | 23.5 |
Percentage of participants achieving dyslipidemia improvement (Low-density lipoprotein cholesterol \<140 milligrams per deciliter (mg/dL), triglycerides \<150 mg/dL, and high-density lipoprotein cholesterol ≥40 mg/dL) was analysed using logistic regression with the following variables: treatment, baseline BMI group, and strata in the model. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no). The estimates (odds ratio and corresponding confidence intervals) were derived using observed data.
| Percentage of Participants | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percentage of Participants Who Had Improvements in Dyslipidemia | 60.9 | 57.4 | 63.6 | 65.2 |
Percentage of participants achieving HbA1c \<6.5% was analysed using logistic regression with the following variables: baseline, treatment, baseline BMI group, and sex in the model, including treatment-by-baseline and treatment-by-sex interaction terms.
| Percentage of Participants | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percentage of Participants Who Achieve Hemoglobin A1c (HbA1c) Target Value (<6.5% [48 mmol/Mol]) | 0 | 31.25 | 45.45 | 78.57 |
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).
| Square Centimeter (cm^2) | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Mean Change From Baseline in Visceral Adipose Tissue (VAT) at Week 72 | -7.20 ± 5.220 | -47.5 ± 5.519 | -52.3 ± 8.043 | -49.3 ± 6.526 |
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).
| Centimeter | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Mean Change From Baseline in Waist Circumference at Umbilical Level at Week 72 | -0.063 ± 0.592 | -3.67 ± 0.845 | -5.87 ± 0.851 | -5.67 ± 0.909 |
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).
| millimeters of mercury (mmHg) | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Mean Change From Baseline in Systolic Blood Pressure (SBP) at Week 72 | -0.055 ± 1.415 | -5.08 ± 1.673 | -3.84 ± 1.636 | -4.36 ± 1.342 |
Values represented as LS means are model-based estimates (MBE) of the unconditional average treatment effect on the log-transformed scale. MBE was calculated using an ANCOVA model for log(Actual Value/Baseline), including log-transformed baseline, treatment, baseline BMI group, and strata (defined by joint levels of sex \[female, male\] and baseline type 2 diabetes status \[yes, no\]) as covariates, with treatment-by-log(baseline) and treatment-by-strata interaction terms included in the model.
| percent change | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percent Change From Baseline in Non-High Density Lipoprotein (Non-HDL) at Week 72 | 0.05 ± 1.711 | -6.91 ± 2.270 | -10.20 ± 2.395 | -10.75 ± 2.352 |
Values represented as LS means are model-based estimates (MBE) of the unconditional average treatment effect on the log-transformed scale. MBE was calculated using an ANCOVA model for log(Actual Value/Baseline), including log-transformed baseline, treatment, baseline BMI group, and strata (defined by joint levels of sex \[female, male\] and baseline type 2 diabetes status \[yes, no\]) as covariates, with treatment-by-log(baseline) and treatment-by-strata interaction terms included in the model.
| percent change | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percent Change From Baseline in High Density Lipoprotein (HDL) at Week 72 | 7.37 ± 2.079 | 5.75 ± 2.314 | 8.62 ± 2.628 | 5.17 ± 2.199 |
Values represented as LS means are model-based estimates (MBE) of the unconditional average treatment effect on the log-transformed scale. MBE was calculated using an ANCOVA model for log(Actual Value/Baseline), including log-transformed baseline, treatment, baseline BMI group, and strata (defined by joint levels of sex \[female, male\] and baseline type 2 diabetes status \[yes, no\]) as covariates, with treatment-by-log(baseline) and treatment-by-strata interaction terms included in the model.
| percent change | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percent Change From Baseline in Triglycerides at Week 72 | -9.61 ± 3.015 | -16.85 ± 4.014 | -24.85 ± 3.976 | -15.64 ± 3.772 |
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).
| milligrams per deciliter (mg/dL) | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Mean Change From Baseline in Fasting Glucose at Week 72 | -0.31 ± 1.564 | -13.98 ± 1.879 | -15.50 ± 2.163 | -17.79 ± 1.713 |
* Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over prolonged periods of time. * Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).
| Percentage of HbA1c | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 72 | 0.041 ± 0.0589 | -0.53 ± 0.0646 | -0.61 ± 0.0976 | -0.62 ± 0.0776 |
Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed model for repeated measures (MMRM) with the following variables: baseline BMI group, baseline-by-time-by-treatment, and strata-by-time-by-treatment interaction terms in the model. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no). An unstructured variance-covariance matrix was used.
| milligrams per liter (mg/L) | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Mean Change From Baseline in High-sensitivity C-reactive Protein at Week 72 | -0.41 ± 0.095 | -0.34 ± 0.146 | -0.61 ± 0.070 | -0.61 ± 0.135 |
Time to event was defined as the duration from randomization to adjudication committee-confirmed diagnosis of type 2 diabetes mellitus (T2D). Descriptive statistics are presented as Kaplan-Meier estimates of time to onset of T2D (in weeks). Time to onset of T2D was also analyzed using a Cox proportional hazards model, with treatment (pooled orforglipron dose groups) and sex as factors and baseline fasting serum glucose as a covariate. Hazard ratios with corresponding confidence intervals were estimated and reported in statistical analysis. Statistical significance between treatment groups was assessed using a two-sided log-rank test.
| Weeks | Placebo QD | 6/ 12/ 36 mg Orforglipron (Pooled Group) |
|---|---|---|
| Time to Onset of Type 2 Diabetes (T2D) | 2.27 (0.38 to 13.74) | 0.78 (0.16 to 3.89) |
The SF-36v2 acute form, 1-week recall assesses participants' health-related quality of life on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. Each domain is scored individually and information from these 8 domains is further aggregated into 2 health component summary scores, a Physical Component Summary, and a Mental Component Summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T scores, with mean of 50 and standard deviation of 10; higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.
| T-score | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Physical Functioning | -0.56 ± 0.596 | 0.15 ± 0.542 | 1.44 ± 0.621 | 0.59 ± 0.599 |
| Role-Physical | -0.12 ± 0.594 | -0.58 ± 0.710 | -0.06 ± 0.584 | -1.11 ± 0.696 |
| Bodily Pain | -1.08 ± 1.075 | -0.58 ± 1.210 | -0.56 ± 1.035 | -1.07 ± 1.269 |
| General Health | -0.80 ± 0.685 | 0.02 ± 0.735 | 1.05 ± 0.745 | 0.01 ± 0.659 |
| Vitality | -0.65 ± 0.883 | -0.82 ± 0.943 | -1.58 ± 0.888 | -0.080 ± 0.979 |
| Social Functioning | -1.19 ± 0.762 | -1.22 ± 0.900 | -0.61 ± 0.731 | -0.48 ± 0.779 |
| Role-Emotional | -1.21 ± 1.068 | -0.22 ± 0.809 | 0.66 ± 0.851 | 0.25 ± 0.816 |
| Mental Health | -1.83 ± 1.003 | -1.65 ± 0.919 | -0.88 ± 0.793 | -1.35 ± 1.050 |
| Physical Component Score | -0.30 ± 0.642 | -0.092 ± 0.765 | 0.84 ± 0.690 | 0.011 ± 0.673 |
| Mental Component Score | -1.59 ± 1.015 | -1.08 ± 0.776 | -0.87 ± 0.819 | -0.21 ± 0.831 |
The IWQOL-Lite-CT is a 20-item, obesity-specific patient reported outcome instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life: physical (7 items), and psychosocial (13 items). A 5-item subset of the physical domain, the physical-function composite is also supported. Items in the physical-function composite describe physical impacts related to general and specific physical activities. All items are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. The two domain scores (Physical and Psychosocial) and composite score (Physical function) range from 0 to 100 with higher scores indicating greater functioning. Raw scores are then linearly transformed to a 0 (worst) -100 (best) scale using: 100×(average item score-1)/4. Higher scores indicate better quality of life/function; lower scores indicate greater impairment.
| score on a scale | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Physical Composite Score | -2.73 ± 1.973 | 2.32 ± 1.968 | 2.67 ± 1.961 | 2.00 ± 1.728 |
| Physical Function Composite Scores | -0.43 ± 1.903 | 3.71 ± 2.039 | 3.08 ± 1.995 | 2.51 ± 1.739 |
| Psychosocial Composite Scores | 1.74 ± 1.637 | 3.47 ± 1.316 | 5.41 ± 1.597 | 4.02 ± 1.360 |
Plasma concentrations of orforglipron were measured at predefined pre-dose and post-dose sampling time points.
| nanograms per milliliter (ng/mL) | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|
| Week 8 | 14.5 ± 8.53 | 13.3 ± 8.16 | 15.2 ± 10.5 |
| Week 16 | 54.3 ± 30.5 | 109 ± 51.1 | 153 ± 111 |
| Week 24 | 26.4 ± 15.3 | 61.6 ± 43.6 | 155 ± 144 |
| Week 36 | 36.7 ± 21.9 | 83.9 ± 98.1 | 173 ± 126 |
| Week 48 | 29.9 ± 15.1 | 55.8 ± 37.2 | 146 ± 108 |
Collected over Baseline up to end of follow-up (up to 74 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo QD | 0/60 (0%) | 5/60 (8.3%) | 47/60 (78.3%) |
| 6 mg Orforglipron QD | 0/61 (0%) | 1/61 (1.6%) | 51/61 (83.6%) |
| 12 mg Orforglipron QD | 0/57 (0%) | 3/57 (5.3%) | 48/57 (84.2%) |
| 36 mg Orforglipron QD | 1/60 (1.7%) | 6/60 (10%) | 51/60 (85%) |
| Event | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Chest painGeneral disorders | 0/60 | 0/61 | 1/57 | 0/60 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/60 | 0/61 | 1/57 | 1/60 |
| Facial paralysisNervous system disorders | 0/60 | 0/61 | 1/57 | 0/60 |
| Myocardial ischaemiaCardiac disorders | 0/60 | 0/61 | 0/57 | 1/60 |
| Sudden hearing lossEar and labyrinth disorders | 0/60 | 0/61 | 0/57 | 1/60 |
| Colitis ischaemicGastrointestinal disorders | 1/60 | 0/61 | 0/57 | 0/60 |
| AppendicitisInfections and infestations | 1/60 | 0/61 | 0/57 | 0/60 |
| Atypical mycobacterial infectionInfections and infestations | 0/60 | 0/61 | 0/57 | 1/60 |
| EpiglottitisInfections and infestations | 1/60 | 0/61 | 0/57 | 0/60 |
| Post procedural infectionInfections and infestations | 0/60 | 0/61 | 0/57 | 1/60 |
| Event | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 21/60 | 16/61 | 24/57 | 12/60 |
| ConstipationGastrointestinal disorders | 5/60 | 22/61 | 16/57 | 19/60 |
| NauseaGastrointestinal disorders | 0/60 | 8/61 | 9/57 | 20/60 |
| DiarrhoeaGastrointestinal disorders | 2/60 | 9/61 | 4/57 | 10/60 |
| VomitingGastrointestinal disorders | 0/60 | 4/61 | 5/57 | 10/60 |
| Covid-19Infections and infestations | 10/60 | 4/61 | 8/57 | 2/60 |
| DyspepsiaGastrointestinal disorders | 0/60 | 2/61 | 5/57 | 8/60 |
| Abdominal discomfortGastrointestinal disorders | 2/60 | 4/61 | 7/57 | 1/60 |
| InfluenzaInfections and infestations | 6/60 | 0/61 | 4/57 | 5/60 |
| Herpes zosterInfections and infestations | 5/60 | 2/61 | 0/57 | 1/60 |
All randomized participants who received at least one dose of study drug.
| Age, Continuous(years) | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD | Total |
|---|---|---|---|---|---|
| Mean | 53.2 ± 11.44 | 53.5 ± 10.34 | 53.5 ± 11.20 | 56.3 ± 11.65 | 54.1 ± 11.17 |
| Sex: Female, Male(Participants) | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD | Total |
|---|---|---|---|---|---|
| Female | 23 | 25 | 22 | 24 | 94 |
| Male | 37 | 36 | 35 | 36 | 144 |
| Ethnicity (NIH/OMB)(Participants) | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 60 | 61 | 57 | 60 | 238 |
| Race (NIH/OMB)(Participants) | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 60 | 61 | 57 | 60 | 238 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD | Total |
|---|---|---|---|---|---|
| Japan | 60 | 61 | 57 | 60 | 238 |
| Body Weight(Kilogram (Kg)) | Placebo QD | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD | Total |
|---|---|---|---|---|---|
| Mean | 87.78 ± 14.58 | 88.64 ± 13.95 | 88.40 ± 15.18 | 86.69 ± 14.69 | 87.87 ± 14.53 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jul 2023 to primary completion in Jun 2025, 22 months.
Results were first posted in Jul 2026, 1 year 1 month after primary completion.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 22 months is close to that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron